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List of abbreviations 
DLCO : diffusion capacity of Carbon monoxide 
GOLD : global initiative of chronic obstructive pulmonary disease 
FEV1 : forced expiratory volume in first second 
FVC : forced vital capacity 
ICS : inhaled corticosteroid 
LABA : long acting beta agonist 
LAMA : long acting anti muscarinic  
mMRC modified medical research council  
SABA : short acting beta agonist 
SAMA : short acting anti muscarinic 
 
ABSTRACT 
Background: COPD is one of the commonest respiratory illnesses that lead great morbidity and disability and 
one of the leading causes of mortality worldwide, also it is a growing field of researches regarding 
reclassification and treatment review there are several methods of classification of COPD patients: GOLD 
system and the newer ABCD assessment tool which is the main field of this research. 
Objective: The aim of the study is to evaluate the patients with COPD using the new ABCD assessment tool and 
comparing it with GOLD classification system in the way of early detection and diagnosis of COPD. 
Patients and methods: A cross-sectional study was conducted at Al-Yarmouk Teaching Hospital - Department 
of Respiratory medicine involving 110 COPD patient evaluated depending on history , physical examination , 
radiological imaging , spirometry and six minute walk test. Then the patients had been grouped according to 
GOLD and ABCD classification systems then comparism between two modalities had been done. 
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Results: The study involved 110 patients aged between 42 and 81 years old ; 92 male and 18 female, male : 
female ratio 5:1. 
We assess the patients according to GOLD module, then the patient had been redistributed according  to ABCD 
assessment tool using FEV1, dyspnea scale utilizing mMRC , and number of exacerbation per year reveal the 
following: No  patient (0%) GOLD 1, 36 patient (32.7%) GOLD2, 42 patient (38.2%) GOLD3, and 32 patient 
(29.1%) GOLD 4 ; while  redistributing the patients according to ABCD module reveals the following: Twenty 
seven patient (24.5%) were class A, 10 patients (9%) were class B , 6 patients (5.5%) class C  and 67 patient 
(61%) of class D ; so there is a significant difference between the different categories of ABCD assessment tool 
as compared to GOLD groups due to the impact of dyspnea scale and number of exacerbations on the 
reclassification. 
Conclusions: ABCD assessment tool may be more accurate and practical than GOLD classification ; ABCD 
assessment tool can be of benefit in early detection and management of early COPD cases more than the GOLD 
system. 
Recommendations: utilization of ABCD assessment tool in early detection , diagnosis , and follow up of 
patients with COPD. 
 
INTRODUCTION: 
Overview of COPD 
Chronic obstructive pulmonary disease (COPD) is a general name for the chronic air flow obstruction that 
develops most often as a result of chronic tobacco smoking, but also after exposure to biomass fuels. The 
pathology of COPD encompasses a variety of pathologic lesions in the airways, lung parenchyma, and 
pulmonary vasculature, and these lesions can be correlated, to a greater or lesser degree, with changes in 
pulmonary function tests and clinical appearances. In general, although the mechanisms involved are complex, 
airflow obstruction can be attributed largely to a marked increase in airway resistance secondary to a variable 
mix of structural abnormalities involving all or many of the compartments of the airway. However, in individual 
cases, it may be difficult to prove associations between physiologic abnormalities and pathologic changes.  
COPD is a disorder that is characterized by slow emptying of the lung during a forced expiration. In practice, 
this is measured as the forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio, and the 
arbitrary definition of airflow obstruction is generally taken to be an FEV1/FVC ratio lower than 0.70.(1) 
The diagnosis of COPD is usually limited to individuals who have chronic airflow obstruction associated with 
tobacco smoke or some other noxious inhalant, and it is usually not difficult to distinguish it from other causes of 
chronic airflow obstruction. The most commonly associated clinical disorders associated with COPD are 
emphysema and chronic bronchitis. Emphysema is defined anatomically by airspace enlargement due to 
disappearance of alveolar septae. This leads to the characteristic loss of elastic recoil, which, in turn, causes 
slowing of airflow from the lungs, hyperinflation, and air trapping . 
Chronic bronchitis is characterized by chronic cough and sputum production, which is present in about one out 
of three people with early COPD. Chronic cough and sputum production in cigarette smokers is often, but not 
always, associated with chronic airflow obstruction. When chronic mucus hypersecretion is associated with 
airflow obstruction, it is often called chronic obstructive bronchitis. (2) 
Patients with COPD also have small- and medium-sized airway involvement with inflammation, narrowing, 
tortuosity, mucus plugging, and fibrosis that contributes to the airflow limitation. 
As the disease evolves, there is obliteration of small airways. Some patients with a long-standing history of 
asthma develop airflow obstruction that is not completely reversible, episodes of cough and wheeze, and chronic 
sputum production. These individuals are often classified as having chronic asthmatic bronchitis and tend to 
have a somewhat better prognosis for survival than those with typical tobacco-related COPD. 
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Natural History of COPD 
COPD results from an increase in the rate of decline in lung function over time. Normal nonsmoking adults lose 
FEV1 at a rate of 30 mL/year, thought to be the consequence of the aging-related loss of elastic recoil of the 
lung. Persons who develop COPD may start in early adulthood with lower levels of lung function and also have 
increased rates of decline. Studies of patients with COPD show an average annual decline in FEV1 of 45 to 69 
mL/yr. 
However, there may be considerable heterogeneity between patients and over time.(3) 
People who discontinue smoking with mild to moderate degrees of airflow obstruction cease the rapid decline in 
FEV1, and have better survival (4) 
Because there are many years of asymptomatic decline in lung function, it is possible to diagnose COPD with 
forced expiratory spirometry before the disease is apparent and implement aggressive smoking intervention 
programs. 
There is a consensus that   smokers with respiratory symptoms should be tested for COPD   with spirometry. 
However, there is debate      whether it is of value to screen for COPD  among   all cigarettes smokers.(5) 
 
Patients with advanced COPD may restrict their activities to a bed-and-chair lifestyle because of severe exercise 
incapacitation. This limitation can lead to social isolation, depression, and skeletal muscle deconditioning, 
which, in turn, further restrict activity and impair quality of life. Protein and calorie malnutrition occurs as the 
consequence of impaired nutritional intake caused by dyspnea. Malnutrition is augmented by increased 
metabolic demands caused by increased basal oxygen consumption, inefficient skeletal muscle oxygen 
utilization, and cachexia-producing cytokines such as tumor necrosis factor-α (TNF-α). (6) 
Several factors have been identified that predict poor survival in  COPD. These include low FEV1, active 
smoking status, hypoxemia, poor nutrition, the presence of cor pulmonale, resting tachycardia, low exercise 
capacity, severe dyspnea, poor health–related quality of life, anemia, frequent exacerbations, comorbid illnesses, 
and low DCO. (7) 
 
Aim of the study: 
The aim of the study is to evaluate the patients with COPD using the  ABCD assessment tool and comparing it 
with GOLD classification system extrapolating advantages and disadvantages of both systems, evaluation of 
treatment modalities , compliance with treatment , and suggesting future plans to improve management and 
follow up of COPD patients. 
 
Patients and methods: 
A cross-sectional study was conducted at Al-Yarmouk Teaching Hospital - Department of Respiratory medicine 
in Baghdad -Iraq  (from the period of January 2017 to January 2018) involving 110 patient with COPD. 
 
Detailed medical history, history of exposure to smoking or noxious materials, history of exacerbations and 
physical examination had been taken . All patients had been investigated with chest imaging , 
electrocardiography ,echocardiography to exclude comorbidities; and the diagnosis of COPD, classification of its 
severity, and progression of the disease had been done  with spirometry. The FEV1/FVC ratio, reflecting the rate 
of emptying of the lung, is used to define the presence of an obstructive ventilatory defect, commonly defined as 
a ratio less than 0.70 or below the lower limit of normal. Once airflow obstruction is established, the severity of 
the airflow limitation is classified by the reduction of FEV1 compared with a healthy reference population , 
Table1 (8) 
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Based on symptoms and risk of exacerbations, individuals are grouped into one of four different patient 
categories (see Fig. 1). The categories are informative for determining prognosis and treatment of COPD .(1) 
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Figure 1  Combined COPD assessment. An understanding of the impact of COPD on an individual patient 
combines assessment of  symptoms and future risk of exacerbation. To use this figure, first assess symptoms 
with the modified medical research council (mMRC) or COPD assessment test (CAT) scale and determine if the 
patient has less symptoms (mMRC <2 or CAT <10) or more symptoms (mMRC ≥2 or CAT ≥10). Next, assess 
the risk of future exacerbation by determining prior exacerbation history and severity of airflow limitation with 
high risk of future exacerbation in individuals with GOLD airflow classification 3 to 4 or ≥2 exacerbations in the 
prior year (future risk should be determined by the method indicating higher risk). With this figure, individuals 
are stratified into one of four categories (A, B, C, D). which helps describe the burden of disease and informs 
potential treatments. (Reproduced with permission from Global Strategy for the Diagnosis, Management, 
Prevention of COPD, © Global Initiative for Chronic Obstructive Lung Disease (GOLD), all rights reserved. 
Available from http://www.goldcopd.org.) 
 
Inclusion criteria involving those patient aging 40 years or more who are current or x-smokers or under long 
time of exposure to noxious stimuli with (post bronchodilator FEV1/FVC <=70% of predicted) documented on 
spirometry. 
The exclusion criteria are:   
1-Ashtma and asthma COPD overlap. 2- Bronchogenic carcinoma,3-Advance congestive heart failure, 4-Severe 
pulmonary hypertension , 5-Patient incapable of ambulation due to limb amputation or orthopedic problems in 
which six minutes walk test and mMRC cannot be appreciated 6-Broncheictasis. 7- Interstitial lung disease. 8-
Active pulmonary tuberculosis. 9-Patient with acute exacerbation of COPD. 
 
The patients had been evaluated using GOLD classification and the new ABCD assessment tool utilizing FEV1, 
mMRC dyspnea scale and number of exacerbations per year. 
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Treatment of the patients according to their GOLD and ABCD groups and compliance with COPD medications 
and vaccination history had been evaluated. 
 
RESULTS 
 The study involved 110 patients between the ages 42 and 81 years old ; 92 male and 18 female, male : female 
ratio 5:1 
Seventy nine  patient (71.8%) are current smokers and 31 (28.2%) were  x-smokers , there is no patient who had 
been non smoker. 
Thirty two patients was inpatients (29.1%) while 78 (70.9%) were outpatients. 
From the medical history we found that 17 patients (15.5%) with equal or more than two exacerbation per year, 
40 patient (36.4%) had one exacerbation and 53 patients (48.2%) with no history of exacerbation ;Table 2 
 
 
 
Table2 Age , sex , smoking status, admissions, and exacerbations 
 
 
We classify the patients according to GOLD system, then the patient had been redistributed according  to ABCD 
assessment tool using FEV1, dyspnea scale utilizing mMRC , and number of exacerbation per year reveal the 
following: No  patient (0%) GOLD 1, 36 patient (32.7%) GOLD2, 42 patient (38.2%) GOLD3, and 32 patient 
(29.1%) GOLD 4 ; while  redistributing the patients according to ABCD assessment tool reveals the following: 
Twenty seven patient (24.5%) were class A, 10 patients (9%) were class B , 6 patients (5.5%) class C  and 67 
patient (61%) of class D ; so there is a significant difference between the different categories of ABCD system as 
compared to GOLD groups due to the impact of dyspnea scale and number of exacerbations on the 
reclassification Figure 2, figure 3 , table 3. 
 
 No % 
Age (years) 40---49 14 12.7 
50---59 30 27.3 
60---69 36 32.7 
70---79 26 23.6 
=>80y 4 3.6 
Mean±SD(Range) 61.9±10.0 (42-81) 
Gender Male 92 83.6 
Female 18 16.4 
Smoking Smoker 79 71.8 
X-Smoker 31 28.2 
Admission In-patient 32 29.1 
Out-patient 78 70.9 
Exacerbation (No/years) No 53 48.2 
One 40 36.4 
Two and more 17 15.5 
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Figure 2 reclassification of patients from GOLD to ABCD module 
 
Table 3 reclassification of patient into subgroups 
 ABCD  
A B C D 
GOLD  1 - - - - 
2 26 10 - - 
3 1 - 6 35 
4 - - - 32 
      
 
Number
0
20
40
60
80
A B C D
GOLD 1 GOLD2
GOLD3
GOLD4
27
10
6
67
0
36
42
32A
x
is
 T
it
le
A B C D GOLD 1 GOLD2 GOLD3 GOLD4
Number 27 10 6 67 0 36 42 32
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Figure 3: schematic presentation of redistribution of patients from GOLD to ABCD classification system. 
 
 
The steady transition of FEV1 among subclasses of GOLD is less clear in ABCD assessment tool in which there 
is integration among the groups because there were another criteria for the classification of patients rather than 
depending on one criterion i.e FEV1. Figure 4; but the transition is still significant statistically in both systems, 
table 4 
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Figure 4  Comparative trend of FEV1 between the GOLD and ABCD classification systems  
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Table 4 range and significance of FEV1 among all groups 
 
 
 
 
 
 
 
Seventy nine patient (71.8%) were on regular treatment according to GOLD module , the other 31 patient ( 
28.2%) were on no regular therapy; Figure 5 
 
Figure 5: classification of patients according to treatment (treated vs non-treated) 
 
Of those  patient on regular treatment the majority were non-compliant with treatment 45 patient (57%) and 34 
patient (43%) are compliant; figure 6. 
79(71.8%)
31(28.2%)
0 20 40 60 80 100
On treatment
On no treatment
Treatment
Treatment
GOLD P value  ABCD P value 
1x2 -  AxB 0.015* 
1x3 -  AxC 0.0001* 
1x4 -  AxD 0.0001* 
2x3 0.0001*  BxC 0.015* 
2x4 0.0001*  BxD 0.0001* 
3x4 0.0001*  CxD 0.003* 
*Significant difference between two independent means using Students-t-test at 0.05 level. 
 FEV1 P value 
GOLD 1 - 0.0001* 
2 61.2±9.8 (50-78)  
3 40.0±6.0 (30-49)  
4 23.5±3.9 (18-29)  
ABCD A 62.9±10.8 (42-78) 0.0001* 
B 54.7±4.7 (50-64)  
C 44.7±5.2 (38-49)  
D 31.7±9.3 (18-48)  
*Significant difference among four independent means using ANOVA test at 0.05 level. 
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Figure 6 : illustration of patients compliance with treatment. 
 
 
Regarding patient receiving treatment  higher percent of patients matching class therapy is group D in which 41 
patient (61.2%) patients are matched compared with only  (10) patient 37%, (2) patients 20% and (2) patients  
33.3% for class A, B and C respectively; Figure 7. 
 
Figure7 : therapy match among ABCD group 
 
34(43%)
45(57%)
0
5
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Regarding the treatment of the patients, 45 patient (40.9%) of patient use SABA, 6 patients (5.5%) use SAMA, 
53 patient (48.2%) use LABA/ICS, 8 patients (7.3%) use LAMA, 10 patients (9.1%) use oral steroids, and 12 
patient (10.9%) use theophylline . Table 5 
Table 5 : Treatment of the patients and significance with therapy 
 
 
P value Treated with SABA SAMA LABA/STR LAMA 
GOLD  0.0001* 0.011* 0.003* 0.019* 
ABCD  0.001* 0.254 0.002* 0.429 
 
 
Regarding vaccination programs only 31 patient (28.2%) had been vaccinated for Influenza vaccine but only 8 
patients (7.3%) had received pneumococcal vaccine. figure 8 
 
 
 
 SABA SAMA LABA/ICS LAMA ORAL 
STEROID 
THEOPHYLL
INE 
A 3 0 7 0 2 4 
B 2 0 2 0 0 0 
C 1 0 2 0 0 0 
D 39 6 42 8 8 8 
OVERAL
L 
45 6 53 8 10 12 
 No % 
Treated with SABA Yes 45 40.9 
No 65 59.1 
SAMA Yes 6 5.5 
No 104 94.5 
LABA/inhaled steroids Yes 53 48.2 
No 57 51.8 
LAMA Yes 8 7.3 
No 102 92.7 
Oral steroids Yes 10 9.1 
No 100 90.9 
Theiophylline Yes 12 10.9 
No 98 89.1 
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 Figure 8 Vaccination in patients with COPD 
 
Six minute walk test had been applied for COPD patients and revealed higher durability i.e >350m is among 
category A (81.5%) compared with only (3%) among category D; meanwhile (59.7%) of category D cannot 
maintain >150 m.; table 6 
 
Table6: six minute walk test among patients classes of ABCD  
SIX MINUTE 
WALK TEST 
<150 150-249 250-349 >350 
A _ 2 3 22 
B 2 4 2 2 
C _ 2 _ 4 
D 40 16 9 2 
 
Discussion 
This study demonstrate that there is significant difference in male:female ratio in COPD which was almost 5:1 
compared with the usual figures published in most references which reveals that male:female ratio is almost 
equal, this difference possibly referred to the fact that most of the published studies focused on the incidence in 
developed countries, the social limitations that make most of the female subject deny smoking, lower level of 
smoker females compared with smokers male in our society in the past decades and possibly small sample size. 
This study also disclose that there is no subject fitting the criteria of GOLD 1 possibly due to delay in 
presentation of COPD patients until he/she had been symptomatic , complaining of acute exacerbations , under 
estimation of respiratory cause of dyspnea in smokers with comorbidities , and lack of screening programs for 
early detection of COPD. 
79(64.5%)
31(28.2%)
8(7.3%)
0
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50
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According to the results of this study the overall COPD case who had been treated and followed up depending on 
the GOLD module is preferred to be switched to the new modality i.e. ABCD assessment tool in which more 
variables had been applied to classify patient to treatment groups and because at an individual level , FEV 1 is an 
unreliable marker of severity of breathlessness, exercise limitation, health status   impairment.(9) 
In this study most of the cases shifted toward both extremes (either of A subgroup in which treatment is simple 
or D subgroup where the treatment and follow up is more complicated) (figure2 and 3); so the use of other 
variables other than only FEV1 will result in a possible improvement  in evaluation , reclassifying, early 
detection of functional status impairment and by the end accurate management . By comparism with the latest 
study published study by  Sonia Coton et al: we compared the strengths of association of each classification with 
quality of life (QoL), MRC dyspnea score and the self-reported exacerbation rate. Agreement between 
classifications was only fair (10) . 
There is shifting toward early diagnosing COPD cases with the new modality  (group A  27 patient Vs zero 
patient for GOLD 1) which reflect the fact that COPD  had not been given importance for early detection and 
waiting COPD patient to be present to the  physician only following development of symptoms of dyspnea or 
suffering from exacerbation  to be noticed . 
Because this study had not revealed any patient with GOLD 1 but still 27 of group A of ABCD , there may be 
better to utilize of ABCD  assessment tool  in  detection of early  COPD and hence early management. 
 
If we compare this study to the latest Saudi COPD study The prevalence of chronic obstructive pulmonary 
disease in Riyadh, Saudi Arabia: a study 2015 by  M. Al Ghobain et al (11), which show that The prevalence of 
COPD stage 1 or higher based on LLN was (3.2%),so  there may be 3-4 % of our population had not been 
diagnosed if we still pursuit GOLD module, and these population need to be considered in the future COPD 
screening programs . 
 
The impact of number of exacerbations / year and dyspnea scale mMRC shifted most of the patients from lower 
GOLD class 3 to group D of ABCD (35 of 42) and that advance enough cases i.e. GOLD 4 FEV1<=30% are all 
of group D in which the number of exacerbations and level of mMRC were  high and is proportional to low 
FEV1, figure 3. 
 
The two intermediate groups of GOLD system i.e. 2 and 3 had been affected as well by the effect of number of 
exacerbations and mMRC scale by the following:, shifting number of GOLD 2 from 36 to 10 group B , 42 
patient of GOLD 3 to 6 of group C. fig 2 table 2. 
 
All these facts urge against the use of FEV1 as a an only parameter for grouping COPD patients and considering 
other measures mentioned before. 
 
This  study  also signify that high number of COPD patients had not been treated 31 patient (28.2%) ,figure 5, 
and among those on treatment 45 patient (57%) are non-compliant, figure 6, and still low percent of patients are 
under treated if they had been classified according to ABCD assessment tool especially in the first three groups 
(A,B and C), but still higher percent of patients in group D is matching their treatment  ( 41 of 67) 61.2%, may 
be related to frequency of exacerbations and high burden of symptoms if we use ABCD assessment tool . figure 
7 
  
Regarding the treatment of the patients the use of SABA and combination of LABA/ inhaled steroids were the 
most frequently used among all ABCD groups (P value 0.001 and 0.002 respectively). But  the use of SAMA 
and LAMA, is still not significant despite their efficacy and role of lowering exacerbation rates in managing 
COPD   ( P value 0.254 and 0.429 respectively) may be because of high cost and delay onset of action as 
compared with beta agonists. Table 5 
 
Influenza vaccination can reduce serious illness (such as lower respiratory tract infection requiring 
hospitalization) and death in COPD patients. Only a few studies have evaluated exacerbations and they have 
shown significant reduction in the total number of exacerbations per vaccinated subject compared with those 
who received placebo (12) . In our study only small proportion were received flu vaccine 31 (28.2%) , and lower 
number received pneumococcal vaccine 8 (7.3%) . A systematic review of injectable vaccines in COPD patients 
identified seven studies for inclusion (two trials of a 14-valent vaccine and 5 trials of a 23-valent injectable 
vaccine) and observed reductions in the incidence of pneumonia and acute exacerbations that did not reach 
statistical significance (12,13). 
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Smoking is the most important etiological element in the development of COPD and all the patient were current 
or x-smoker, due to the lack of effective smoking control action, it is expected that COPD will be a major health 
problem in the near future, with a very high demand on health services, so still active smoking is associated with 
more exacerbations. 
Finally an important limitation in our study is that lack of cases in GOLD 1 subgroup , the low number of female 
patients and the high incidence of comorbidities that results in exclusion of some presumed COPD  cases from 
this study. 
 
Conclusions 
From this study we conclude the followings: 
1- No patient of group 1 of GOLD system had been detected in this study. 
2- Most of the patients in GOLD system had been reclassified into different treatment and prognostic groups by 
ABCD module. 
3- ABCD assessment tool may be of more benefit in early detection and management of early COPD cases than 
the GOLD module. 
4- Significant percentage of COPD patients are not treated appropriately or not treated at all. 
5- Significant percent of treated patients are not compliant with their treatment. 
6- The vast majority of COPD patient were not vaccinated and the majority still active smokers. 
 
Recommendations 
1- We my need a larger multicenter study involving  more COPD patients for more accurate assessment of 
COPD in Iraq. 
2- Better utilization of ABCD module in diagnosis and follow up COPD patients. 
3- Optimization of COPD management and encourage patients to adhere to their medications. 
4- Encourage vaccination for pneumococcal and flu vaccine in newly diagnosed and non- vaccinated COPD 
patients. 
5- Encourage stop smoking in the society and keeping health authorities informed about strategic planning 
requirements to fight against the increase in smoking and worsening air pollution.  
 
6- Educate the treating stuff in general practitioner, internal medicine, and chest clinics to better utilizing history 
of exacerbations , dyspnea scale as well as spirometry in diagnosing and follow up COPD patients. 
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